000274048 001__ 274048
000274048 005__ 20250127091413.0
000274048 0247_ $$2ISSN$$a2510-9642
000274048 0247_ $$2doi$$a10.1055/a-2446-6877
000274048 0247_ $$2pmid$$apmid:39572152
000274048 0247_ $$2ISSN$$a0176-3679
000274048 0247_ $$2ISSN$$a0031-7098
000274048 0247_ $$2ISSN$$a0720-4280
000274048 0247_ $$2ISSN$$a1439-0795
000274048 037__ $$aDZNE-2025-00029
000274048 041__ $$aEnglish
000274048 082__ $$a610
000274048 1001_ $$aHaeckert, Jan$$b0
000274048 245__ $$aImpact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation.
000274048 260__ $$aStuttgart [u.a.]$$bThieme$$c2025
000274048 3367_ $$2DRIVER$$aarticle
000274048 3367_ $$2DataCite$$aOutput Types/Journal article
000274048 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736940368_25677
000274048 3367_ $$2BibTeX$$aARTICLE
000274048 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274048 3367_ $$00$$2EndNote$$aJournal Article
000274048 520__ $$aThis study evaluates the impact of Parkinson disease (PD) medication in advanced PD on neuropsychological performance, psychiatric symptoms, impulsivity and the quality of life. In the 4-year period 27 patients with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean age: 58.9±7.1, disease duration: 10.0 years±4.2) were examined preoperatively. We hypothesized that a high dosage of PD medication or current use of dopamine agonists affect cognitive functioning and psychiatric wellbeing.We performed two subgroup analyses with low versus high levodopa-equivalent Dosage (LED) medication and without versus with dopaminagonistic medication.The neuropsychological testing revealed significant differences in the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500, Z=- 2.475, p=0.012) and in the subtest of the semantic fluency of Regensburg verbal fluency test (RWT) (t(25)=- 2.066, p=0.049) with better results for patients without dopaminagonistic medication. Pearson correlation analyses of LED in correlation with the clinical and cognitive dependent variables showed a significant higher PANSS total score in patients with higher LED medication (r=0.491, p=0.009). In addition, lower LED treatment was associated with significant higher scores in the impulsivity perseverance subtest (r=- 0.509, p=0.008).In conclusion, we found lower LEDs to be correlated with a better perseverance in the impulsivity test and additional treatment with a dopamine agonist influenced some verbal learning tasks and the PANSS total score in patients with advanced PD. This should be considered prior to DBS surgery.
000274048 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274048 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274048 650_7 $$2NLM Chemicals$$aAntiparkinson Agents
000274048 650_7 $$2NLM Chemicals$$aDopamine Agonists
000274048 650_7 $$046627O600J$$2NLM Chemicals$$aLevodopa
000274048 650_2 $$2MeSH$$aHumans
000274048 650_2 $$2MeSH$$aParkinson Disease: drug therapy
000274048 650_2 $$2MeSH$$aParkinson Disease: psychology
000274048 650_2 $$2MeSH$$aParkinson Disease: complications
000274048 650_2 $$2MeSH$$aParkinson Disease: therapy
000274048 650_2 $$2MeSH$$aDeep Brain Stimulation
000274048 650_2 $$2MeSH$$aMale
000274048 650_2 $$2MeSH$$aMiddle Aged
000274048 650_2 $$2MeSH$$aFemale
000274048 650_2 $$2MeSH$$aNeuropsychological Tests
000274048 650_2 $$2MeSH$$aAged
000274048 650_2 $$2MeSH$$aAntiparkinson Agents: therapeutic use
000274048 650_2 $$2MeSH$$aQuality of Life
000274048 650_2 $$2MeSH$$aDopamine Agonists: therapeutic use
000274048 650_2 $$2MeSH$$aLevodopa: therapeutic use
000274048 650_2 $$2MeSH$$aCognition: drug effects
000274048 7001_ $$aRoeh, Astrid$$b1
000274048 7001_ $$aKarch, Susanne$$b2
000274048 7001_ $$0P:(DE-2719)2810825$$aKoeglsperger, Thomas$$b3$$udzne
000274048 7001_ $$aHasan, Alkomiet$$b4
000274048 7001_ $$aPapazova, Irina$$b5
000274048 773__ $$0PERI:(DE-600)2041961-2$$a10.1055/a-2446-6877$$gVol. 58, no. 1, p. 5 - 13$$n1$$p5 - 13$$tPharmacopsychiatry$$v58$$x0176-3679$$y2025
000274048 909CO $$ooai:pub.dzne.de:274048$$pVDB
000274048 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000274048 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274048 9141_ $$y2025
000274048 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000274048 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOPSYCHIATRY : 2022$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000274048 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000274048 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000274048 980__ $$ajournal
000274048 980__ $$aVDB
000274048 980__ $$aI:(DE-2719)1111015
000274048 980__ $$aUNRESTRICTED